<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03619174</url>
  </required_header>
  <id_info>
    <org_study_id>LIBERATE International</org_study_id>
    <nct_id>NCT03619174</nct_id>
  </id_info>
  <brief_title>LIBERATE International</brief_title>
  <official_title>LIBERATE International: Evaluation of the Safety and Efficacy of the Viveve Treatment for Stress Urinary Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viveve Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Viveve Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, double-blind, sham-controlled clinical study. The study is
      designed to demonstrate that active is superior to sham for the efficacy endpoints and is
      deemed to have appropriate safety as compared to sham.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately ninety-nine (99) subjects meeting the inclusion/exclusion criteria will be
      randomized in a 2:1 ratio to either the active or sham group. Randomization will be
      stratified by study site, with a maximum of 21 subjects randomized in an individual site.
      Subjects will be followed up with at 10 days and at 3 and 6 months post-treatment. Subjects
      will be assessed for adverse events at all study contacts and visits from the time the
      informed consent is signed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 24, 2018</start_date>
  <completion_date type="Actual">July 5, 2019</completion_date>
  <primary_completion_date type="Actual">July 5, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CFB in 1-hour Pad Weight Test</measure>
    <time_frame>6 months post-treatment</time_frame>
    <description>Change from baseline in the 1-hour pad weight test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Adverse Event Reporting</measure>
    <time_frame>6 months post-treatment</time_frame>
    <description>Safety as assessed by Adverse Event reporting</description>
  </secondary_outcome>
  <other_outcome>
    <measure>UDI-6</measure>
    <time_frame>3 and 6 months post-treatment</time_frame>
    <description>Validated urinary incontinence questionnaire titled Urogenital Distress Inventory-6 (UDI-6)</description>
  </other_outcome>
  <other_outcome>
    <measure>ICIQ-UI-SF</measure>
    <time_frame>3 and 6 months post-treatment</time_frame>
    <description>Validated urinary incontinence questionnaire titled International Consultation on Incontinence Modular Questionnaire-Urinary Incontinence Short Form (ICIQ-UI-SF)</description>
  </other_outcome>
  <other_outcome>
    <measure>I-QOL</measure>
    <time_frame>3 and 6 months post-treatment</time_frame>
    <description>Validated urinary incontinence questionnaire titled Incontinence Quality of Life (I-QOL)</description>
  </other_outcome>
  <other_outcome>
    <measure>FSFI</measure>
    <time_frame>3 and 6 months post-treatment</time_frame>
    <description>Validated questionnaire titled The Female Sexual Function Index (FSFI)</description>
  </other_outcome>
  <other_outcome>
    <measure>Voiding Episodes per Day</measure>
    <time_frame>6 months post-treatment</time_frame>
    <description>Voiding episodes per day tracked via daily voiding diary.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Stress Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Active Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sub-therapeutic dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Viveve Treatment</intervention_name>
    <description>The Viveve system is a monopolar radiofrequency system that uses surface cooling and radiofrequency (RF) energy delivery to provide a non-surgical and minimally-invasive approach to generate heat within the submucosal layers of vaginal tissue while keeping the surface cool.</description>
    <arm_group_label>Active Treatment</arm_group_label>
    <arm_group_label>Sham Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Signed and dated ICF

          -  Pre-menopausal females

          -  Documented diagnosis of SUI

        Exclusion Criteria:

          -  Pregnant or planning to become pregnant within the year

          -  Undergone other SUI treatments (excluding Kegels)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stacie Bell, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Viveve Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LIBERATE In't Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LIBERATE Int'l Site</name>
      <address>
        <city>Pointe-Claire</city>
        <state>Montreal</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LIBERATE Int'l Site</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LIBERATE Int'l Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LIBERATE Int'l Site</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LIBERATE Int'l Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 26, 2018</study_first_submitted>
  <study_first_submitted_qc>August 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2018</study_first_posted>
  <last_update_submitted>July 25, 2019</last_update_submitted>
  <last_update_submitted_qc>July 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>incontinence</keyword>
  <keyword>urine</keyword>
  <keyword>urinary</keyword>
  <keyword>pee</keyword>
  <keyword>leak</keyword>
  <keyword>SUI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

